Healius Limited · ASX:HLS
Healius — Merger or Acquisition (December 2021)
14 slides from Healius's merger presentation, Dec 17, 2021
Slide 1: Acquisition of Agilex Biolabs and entry into clinical research services market
For personal use only Acquisition of Agilex Biolabs and entry into clinical research services market 17 December 2021
Slide 2: Contents
Contents For personal use only Page Transaction overview 3 Business overview 6 Market overview 9 Appendix 13 2
Slide 3: 1. Transaction overview
1. Transaction overview For personal use only 3
Slide 4: Transaction overview
Transaction overview For personal use only Healius to acquire 100% of Agilex Biolabs, one of Australia’s leading bioanalytical laboratories • Healius to acquire 100% of Agilex Biolabs (“Agilex”) for an enterprise value of $301.3m(1)(2) • Agilex is one of Australia’s leading bioanalytical laboratorie
Slide 5: Strategic rationale
Strategic rationale For personal use only Acquiring one of Australia’s leading bioanalytical laboratories A platform for growth via a unique Australian entry point into the attractive global clinical trials sector with 1 opportunities for both organic and inorganic growth Balances Healius’ existin
Slide 6: 2. Business overview
2. Business overview For personal use only 6
Slide 7: Agilex is a recognised leader in Australia
Agilex is a recognised leader in Australia For personal use only One of Australia’s leading bioanalytical laboratories, employing over 100 scientific professionals Geographic reach One of Australia’s leading bioanalytical laboratories, employing over 100 scientific professionals 900+ cumulative pr
Slide 8: Agilex has achieved significant growth in planned work
Agilex has achieved significant growth in planned work For personal use only Agilex has had strong recent growth in planned work which helps to underpin near-term revenue Planned Work(1) ($m) Extensive experience in the highest growth therapeutic areas 36 Broad therapeutic experience (%)(2) 31 16% O
Slide 9: 3. Market overview
9 For personal use only 3. Market overview
Slide 10: Attractive long-term global outlook for bioanalytical laboratory testing
Attractive long-term global outlook for bioanalytical laboratory testing For personal use only Biotech & pharmaceutical R&D spending is growing globally and is increasingly being outsourced Bioanalytical Laboratory Testing Services Market Global market for pharma and biotech R&D outsourcing Long-t
Slide 11: Australia is a destination of choice for clinical trials
Australia is a destination of choice for clinical trials For personal use only Australia has significant speed, quality and cost advantages versus other clinical trial destinations Australian interventional drug trial starts (# of trials) Therapeutics Goods Administration (TGA) has one of the fast
Slide 12: Agilex is highly complementary
Agilex is highly complementary For personal use only The acquisition of Agilex by Healius is a compelling strategic & operational fit Unique Australian entry point into the attractive global clinical trial sector at scale High growth global platform Opportunities for both organic and inorganic g
Slide 13: Appendix
13 For personal use only Appendix
Slide 14: Bioanalytical laboratory testing is essential in clinical trials
Bioanalytical laboratory testing is essential in clinical trials For personal use only Bioanalytical services is the development, validation and implementation of biochemical laboratory assays to characterise a drug and the patients’ response to it to support safe, effective and expedient clinical t